Introduction: During early clinical testing of a
INTRODUCTION
Pharmaceutical innovation is based on cutting edge science with the ultimate aim of improving patients' lives. However, the path from innovation through development is complex and highly regulated [1] with well-defined but proscriptive technical requirements for the conduct of clinical trials [2] . Furthermore, patient outcomes are also dependent on compliance [3] , and those who do not engage, and therefore, do not comply are likely to derive lesser benefit. It is no longer acceptable to rely solely on the scientific output of the clinical study when the patient's experience of the drug and choices made may be of equal importance, both to the sponsor and to the patient. The principal objective in an open-label Phase I oncology study, is to understand safety, tolerability and other aspects of the drug profile, and thus help define a recommended dose for further investigation [4] . A major component in determining this is deciding which dosing regimen is best tolerated by patients for the duration of study treatment.
This is not easy to address with the clinical dataset alone, which is entered by the clinical teams in the clinical trial site, and categorical in the nature of the data collection, particularly recording of adverse events. For example, there may be significant resolution in the severity or distribution of an event which still remains within the same severity category, e.g., mild. As the patients themselves cannot ordinarily share their experiences directly with a clinical study sponsor, it is generally the information in the case report form [5] that is solely relied upon for drug development decisions. In this case, this gives the impression of constancy when in fact, there may have been, to the patient at least, a significant reduction in the treatment burden experienced. Incorporating patient-driven insight, that is shared directly with both the medical teams and study sponsors, into this understanding is likely to provide a step-change in interpretation capability and to result in more informed decisions [6, 7] As the PROACT approach is so radically different to traditionally accepted methodology, and shifts the information flow from the sponsor and/or clinical teams, to the patients who drive and choose content, testing this system for the first time brought with it a high level of uncertainty. Therefore, we developed a pilot system, and conducted a pilot study that was limited in scale so that the utility of PROACT could be explored in the clinical oncology setting, without inadvertently increasing risks in other areas. Furthermore, we conducted in parallel a patient forum meeting to enhance our learning and implementation of the system by gathering information on communication needs within early clinical trials and pulling this into the PROACT approach. It is the learning gathered during the pilot and the correlating patient focus group meeting that is presented in this report.
METHODS

PROACT Design and Development
PROACT was a password-protected mobile application developed with ease of use and security in mind. It had a help function that contains a video on how to use the application, and a link to a technical support team for help with password resets and any technical issues.
The application allowed patients to record messages (audio/video) and for these to be streamed to a server and made instantly viewable to the patient's onsite clinical team who were then able to respond appropriately. Patients received a return video/audio message in a chronologically arranged 'message list' that they were able to view at will.
After a delay of 32 days, the patient's message was sent through to a small group of independent analysts. This delay was to ensure that any adverse event information was discussed between the patient and their onsite clinical team and that all relevant updates were entered into the clinical study database for reporting as per the clinical study protocol.
The analysts removed personally-identifiable information while capturing the patient message which was then relayed to the sponsor's study team for further analysis (see Fig. 1 ).
Patients and medical team members had the ability to trigger deletion of any of their own videos recorded and uploaded to the PROACT system by pressing the 'delete' button within the application. This triggered total deletion of that video and associated information (but not analyzed/anonymized data).
Data Storage and Protection
Rigorous controls were implemented to ensure data protection and patient confidentiality. All connections to the PROACT application were secured via https using a digital certificate.
Within the PROACT environment, encrypted data were hosted by the Safe Harbor Certified Provider (Rackspace) in accordance with national and international standards on data protection [8] [9] [10] . User access to decrypted data was granted at different levels dependent on role (patient, investigator, administrator, sponsor).
Pilot Study Objectives
The pilot study was conducted using a clinical protocol, which had been developed, written and submitted to an Ethics Committee for approval. The objectives were to investigate the uptake and use of PROACT when made available to patients undergoing treatment for cancer in a clinical trial setting and to characterize the information that patients volunteered. The principal focus in this respect was to understand the technicalities and practicalities of the application. The study was also designed to preliminarily assess the potential benefit of receiving direct feedback from patients for the sponsor, and to explore analysis methods that would convert the information into an interpretable dataset while also protecting patient privacy. The objectives were developed with the long-term aim of PROACT being used in a way that fits with patients' day-to-day lives. albeit from a small sample of patients already comfortable with using mobile devices.
Patients' messages were created, transmitted and handled as described previously.
Data Analysis
Data evaluation focused on identifying contextual key words and topics, using manual text analysis of transcribed data.
Patient-identifiable data was removed while capturing the message a patient wanted to convey in an interpretable dataset. To enable this, a hierarchical dictionary and flexible coding database were created to allow for aggregation of data, while linking back to the patient's own words (see Fig. 2 assessed to see whether they were able to capture the core elements of the patient contribution in a format that would be useful for contributing to drug programme decisions.
Ethical Approval
The study received Ethical Research Committee approval (with positive comments regarding steps taken to ensure patient confidentiality and data protection) and it was conducted in accordance with applicable regulatory requirements and other relevant guidelines, such as patient data privacy requirements previously described [8] [9] [10] .
Patient Forum
In parallel with the pilot study, we conducted an interactive meeting with patient and carer 
RESULTS
Patients
Of the 16 patients informed of the PROACT initiative (12 male, 4 female), 8 patients already possessed and used a computer tablet or smartphone and consented to take part. Participating patients were marginally younger (mean age 61 years; range 45-68 years) than those ineligible to participate through lack of access to mobile technology (mean age 67 years; range 51-80 years).
Usage and Information Shared
The use of PROACT varied between individuals, with some patients using the application many times a week and others rarely or not at all (the latter stated that they did not feel that they had much or anything to share). All messages volunteered by patients were very relevant and informative for drug development. Topics covered included the impact of safety and tolerability, relay of self-monitored results (e.g., blood pressure), feedback on study design, and information relating to the formulation of the medications (see Table 1 ). Patient feedback on the PROACT approach itself was also positive, highlighting the patient's role in drug development (e.g., ''It is gratifying to know that I have a role in the development of the drug. To believe that this may help others in the future is a real reward too.''). Fig. 2 Hierarchical dictionary and flexible coding database; terminology tree example. QOL quality of life understanding of tolerability, the impact on patients and the overall consequences (see Table 2 ).
Data Analysis
The coded database was visualized in a series of graphs to explore potential signals (Fig. 3 ). All data points were supported with the patient's own words and these were readily accessible so that the patient's intended message could be seen by the clinical team.
This ability to work with both aggregated individual data provided efficient interpretation and alignment of patient contributions. Thus, the study sponsor was able to (1) spot trends, such as the most frequently talked about topics and the temporal emergence of topics, (2) identify the aspects of study treatment and/or study conduct having most impact on patients, ' 'It is also quite unpleasant to expose my skin to hot water-I don't enjoy a shower or a bath' ' ' 'My skin continues to be dry but is responding to stuff called Bach's rescue cream and is not a problem''
MedDRA medical dictionary for regulatory activities, CTCAE common terminology criteria for adverse events
(a)
Minimal impact on quality of life. Also used to describe if an event had resolved or was improving.
Moderate impact on quality of life. Patient able to generally continue daily activities with some limitation. Also used to describe an ongoing event.
Significant impact on quality of life. Also used to describe a new or worsening event.
No impact on quality of life. Table 3 ). In the following session, patients were briefly told of the PROACT concept and were asked to discuss its potential features and usage (see Table 4 ). The group generally agreed that the concept was advantageous and that having a means to send messages between site visits would provide extra insight into the patient experience.
Patients considered that being able to send messages ad hoc and at scheduled times to both be beneficial, and they considered an option to receive messages, particularly relating to study status, a key attribute. However, they considered that uptake and usage would depend on ease of use, while security features should be pitched at an appropriate level so as to not be off putting. and review the patients simply and quickly between visits. As patients' insight is also aggregated for the overall study population, they also receive a better understanding of drug tolerability, thereby gaining a direct understanding from patients across the whole study and in a non-clinical setting, i.e., at home. This enables better understanding and better patient management of tolerability issues during an ongoing clinical study and builds a 'patient' knowledge base, which may be used for subsequent related studies. Also, the sponsor receives broad insight into the impact the drug is having on patients that includes information related to tolerability, formulation, convenience, and study conduct. This enables assessment of the recommended dose on a comprehensive dataset generated from both the clinical report form and direct patient feedback.
Limitations of this pilot study include the small sample size, the iterative process that led to the development of the coded database (no saturation criteria were used for feedback topics), use of an early version of the application, and the low uptake rate due to patients not possessing the appropriate technology. Of note, feedback from patients on the use of the application itself was positive, but in spite of this, it became apparent that patients, in general, were not aware of the value their contribution could make. Patients sometimes did not share insight in the pilot 
CONCLUSIONS
In summary, PROACT achieved initial proof of concept and delivered a secure end-to-end system that protected patient privacy while providing preliminary patient insight into clinical trial participation. In this respect, it appears to provide a new way of engaging and empowering patients with the potential to change the communication paradigm for an ongoing clinical trial. As previous studies have shown, engaged patients who have the skills, ability, and willingness to help manage their own health have better health outcomes at lower cost to the health system [12] . Further validation of this technology in larger patient cohorts using an enhanced application is ongoing.
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